The group still has its eye on accelerated approval, though genetic testing casts a long shadow.
A handful of small caps, including Sensei and PDS, jumped on Asco abstract data, with much more news to come.
Among late-breaking abstracts whose titles have just gone live two mechanisms have a chance to redeem themselves.
Any signs of efficacy with PRS-343 could help Pieris claw back some of its recent losses, but Her2 targeting is increasingly competitive.
Merus’s anti-Her2/Her3 bispecific could have a future in a new targeted setting.
Eagerly pursuing all the latest fads and trends.